Bousquet J, Godard P, Michel F B
Clinique des Maladies Respiratoire, Hôpital l'Aiguelongue, Centre Hospitalier Universitaire, Montpellier, France.
Eur Respir J. 1992 Oct;5(9):1137-42.
Histamine is an important mediator of asthma. The new anti-histamines which block histamine at the H1-receptor level also possess some anti-allergic properties. At current dosages they appear to be safe. These drugs are effective in the treatment of rhinitis and conjunctivitis but their role in asthma is still under investigation. At a dose higher than usually recommended, they were shown to block exercise-induced asthma and, inconstantly, the early phase reaction after allergen challenge. Their effect on the late phase allergic reaction as well as their clinical efficacy during trials is, however, less consistent. The indication of H1-blockers in the treatment of asthma is therefore limited, especially since doses higher than recommended may lead to adverse reactions.
组胺是哮喘的重要介质。在H1受体水平阻断组胺的新型抗组胺药也具有一些抗过敏特性。以目前的剂量使用，它们似乎是安全的。这些药物对鼻炎和结膜炎有效，但它们在哮喘治疗中的作用仍在研究中。在高于通常推荐剂量时，它们可阻断运动诱发的哮喘，并且偶尔也能阻断变应原激发后的早期反应。然而，它们对迟发性过敏反应的作用以及在试验期间的临床疗效不太一致。因此，H1阻滞剂在哮喘治疗中的适应证有限，特别是因为高于推荐剂量可能会导致不良反应。
